Vertex Pharmaceuticals Forecasts 2026 Revenue in Line With Estimates as New Drugs Gain Traction
Vertex expects 2026 revenue up to 13.1 billion dollars. The firm sees growth from its core cystic fibrosis drugs and new non-opioid painkiller treatments.
Insights:
Vertex Pharmaceuticals Incorporated announced its 2026 revenue guidance on February 12, 2026, projecting a range between $12.95 billion and $13.1 billion. This forecast, released concurrently with the company's fourth-quarter financial results, features a midpoint that aligns with analyst estimates compiled by LSEG. The guidance represents a significant milestone for the US 
US-based biotechnology firm, signaling its near-term financial outlook and the continued diversification of its product mix.
US-based biotechnology firm, signaling its near-term financial outlook and the continued diversification of its product mix.The company attributed the projected revenue to the sustained performance of its cystic fibrosis therapies and anticipated growth from its expanding portfolio of non-cystic fibrosis products. Vertex expects at least $500 million in revenue contributions from these newer treatments during the 2026 fiscal year. This category includes the products Casgevy, Journavx, and povetacicept, marking a quantified shift toward revenue streams outside of its traditional core market.
